


CLAIMS:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 represents $-C_{3-7}$ cycloalkyl optionally substituted by C_{1-3} alkyl;

R^2 represents hydrogen, $-C_{1-6}$ alkyl, $-X-C_{3-8}$ cycloalkyl, $-X$ -aryl, $-X$ -heterocyclyl, $-X$ -

10 heteroaryl, -X-C₃₋₈ cycloalkyl-Y-C₃₋₈ cycloalkyl, -X-C₃₋₈ cycloalkyl-Y-aryl, -X-C₃₋₈ cycloalkyl-Y-heteroaryl, -X-C₃₋₈ cycloalkyl-Y-heterocyclyl, -X-aryl-Y-C₃₋₈ cycloalkyl, -X-aryl-Y-aryl, -X-aryl-Y-heteroaryl, -X-aryl-Y-heterocyclyl, -X-heteroaryl-Y-C₃₋₈ cycloalkyl, -X-heteroaryl-Y-aryl, -X-heteroaryl-Y-heteroaryl, -X-heteroaryl-Y-heterocyclyl, -X-heterocyclyl-Y-C₃₋₈ cycloalkyl, -X-heterocyclyl-Y-aryl, -X-heterocyclyl-Y-heteroaryl, -X-heterocyclyl-Y-
15 heterocyclyl;

X represents a bond or C₁₋₆ alkyl;

Y represents a bond, C_{1-6} alkyl, CO , COC_{2-6} alkenyl, O or SO_2 ;

R^3 represents halogen, C_1 -alkyl, C_1 -alkoxy, cyano, amino or trifluoromethyl;

n is 0, 1 or 2.

20 wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R^2 may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, $=O$, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C_{1-6} alkyl, pentafluoroethyl, C_{1-6} alkoxy, aryl C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxy carbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonyl C_{1-6} alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl C_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido, C_{1-6} alkylamino, C_{1-6} alkylamido, $-R^4$, $-CO_2R^4$, $-COR^4$, C_{1-6} alkylsulfonamido C_{1-6} alkyl, C_{1-6} alkylamido C_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido C_{1-6} alkyl, arylcarboxamido C_{1-6} alkyl, aroyl, aroyl C_{1-6} alkyl, 30 aryl C_{1-6} alkanoyl, or a group $-NR^5R^6$, $-C_{1-6}$ alkyl- NR^5R^6 , $-C_{3-8}$ cycloalkyl- NR^5R^6 , $-CONR^5R^6$, $-NR^5COR^6$, $-NR^5SO_2R^6$, $-OCONR^5R^6$, $-NR^5CO_2R^6$, $-NR^4CONR^5R^6$ or $-SO_2NR^5R^6$ (wherein R^4 , R^5 and R^6 independently represent hydrogen, C_{1-6} alkyl, $-C_{3-8}$ cycloalkyl, $-C_{1-6}$ alkyl- C_{3-8} cycloalkyl, aryl, heterocyclyl or heteroaryl or $-NR^5R^6$ may represent a nitrogen containing heterocyclyl group, wherein said R^4 , R^5 and R^6 groups may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino, $=O$ or trifluoromethyl);
35 or solvates thereof.

2. A compound of formula (I) as defined in claim 1 wherein R¹ represents unsubstituted cyclobutyl, cyclopentyl or cyclohexyl.

3. A compound of formula (I) as defined in claim 2 wherein R¹ represents unsubstituted cyclobutyl.

4. A compound of formula (I) as defined in any one of claims 1 to 3 wherein R² represents:

hydrogen;

-C₁₋₆ alkyl optionally substituted by a -CO₂R⁴ or -CONR⁵R⁶ group;

-X-C₃₋₈ cycloalkyl-Y-heterocyclyl;

-X-aryl-Y-C₃₋₈ cycloalkyl;

-X-aryl optionally substituted by one or two halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, -CO₂R⁴,

-CONR⁵R⁶, -NR⁵COR⁸, -SO₂NR⁵R⁶ or cyano groups;

-X-aryl-Y-heterocyclyl optionally substituted by one or two =O, halogen or R⁴ groups;

-X-heteroaryl optionally substituted by one or two halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, nitro, -OR⁴, -COR⁴, -CO₂R⁴, -NR⁵R⁶, -NR⁵COR⁶, -CONR⁵R⁶ or =O groups;

-X-heteroaryl-Y-aryl optionally substituted by a C₁₋₆ alkylsulfonyl or -NR⁵COR⁶

group;

-X-heteroaryl-Y-heteroaryl optionally substituted by a C₁₋₆ alkyl group;

-X-heteroaryl-Y-heterocyclyl optionally substituted by one or two =O, C₁₋₆ alkyl, -OR⁴ or halogen groups;

-X-heteroaryl-Y-heterocyclyl optionally substituted by one or two =O, C₁₋₆ alkyl, -OR⁴ or halogen groups;

-X-heterocyclyl optionally substituted by a C₁₋₆ alkylsulfonyl, C₁₋₆ alkoxy carbonyl, -CO₂R⁴, -COR⁴ or -COR⁵R⁶ group;

-X-heterocyclyl-Y-aryl optionally substituted by a halogen, cyano, C₁₋₆ alkylsulfonyl, R⁴ or -CONR⁵R⁶ group;

-X-heterocyclyl-Y-heterocyclyl optionally substituted by one or two =O or R⁴ groups;

-X-heterocyclyl-Y-C₃₋₈ cycloalkyl; or

-X-heterocyclyl-Y-heteroaryl optionally substituted by one or two C₁₋₆ alkyl, =O, cyano or -CONR⁵R⁶ groups.

35 5. A compound of formula (I) as defined in claim 4 wherein R² represents

-X-aryl optionally substituted by one or two halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, -CO₂R⁴, -CONR⁵R⁶, -NR⁵COR⁶, -SO₂NR⁵R⁶ or cyano groups;

-X-aryl-Y-heterocyclyl optionally substituted by one or two =O, halogen or R⁴ groups;

40 -X-heteroaryl optionally substituted by one or two halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, nitro, -OR⁴, -CO₂R⁴, -COR⁴, -NR⁵R⁶, -NR⁵COR⁶, -CONR⁵R⁶ or =O groups;

-X-heteroaryl-Y-heterocyclyl optionally substituted by one or two =O, C₁₋₆ alkyl, -OR⁴ or halogen groups; or

-X-heterocyclyl-Y-heterocyclyl optionally substituted by one or two =O or R⁴ groups.

5 6. A compound of formula (I) as defined in claim 5 wherein R² represents:

-X-aryl optionally substituted by one or two halogen, C₁₋₆ alkoxy, -CONR⁵R⁶, -

NR⁵COR⁸ or cyano groups;

-X-aryl-Y-heterocyclyl optionally substituted by one or two =O or halogen groups; unsubstituted -X-heterocyclyl-Y-heterocyclyl;

10 -X-heteroaryl optionally substituted by CON(H)(Me)); or

-X-heteroaryl-Y-heterocyclyl wherein said heterocyclyl group is optionally substituted by an =O group.

7. A compound of formula (I) as defined in claim 6 wherein R² represents:

15 -phenyl optionally substituted by one or two fluorine, methoxy, -CON(H)(Me), -NHCOMe or cyano groups;

-phenyl-pyrrolidinyl optionally substituted by one or two =O or fluorine groups; unsubstituted -piperidinyl-CO-morpholinyl;

-2-pyridinyl or -2-pyrazinyl optionally substituted by CON(H)(Me); or

20 -2-pyridinyl-N-pyrrolidinyl wherein said pyrrolidinyl group is optionally substituted by an =O group.

8. A compound of formula (I) as defined in claim 7 wherein R² represents 4-methylaminocarbonylpyridin-2-yl.

25

9. A compound of formula (I) as defined in any one of claims 1 to 6 wherein X represents a bond or -CH₂-.

30 10. A compound of formula (I) as defined in claim 9 wherein X represents a bond.

11. A compound of formula (I) as defined in any one of claims 1 to 6, 9 or 10 wherein Y represents a bond, CO, SO₂ or -CO-CH=CH-.

35 12. A compound of formula (I) as defined in claim 11 wherein Y represents a bond.

13. A compound of formula (I) as defined in any one of claims 1 to 5 or 9 to 12 wherein R⁴ represents hydrogen, C₁₋₆ alkyl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, aryl, heterocyclyl or heteroaryl optionally substituted by a halogen or C₁₋₆ alkoxy group.

40 14. A compound of formula (I) as defined in any one of claims 1 to 5 or 9 to 12 wherein R⁵ and R⁶ independently represent hydrogen, C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, aryl or heterocyclyl optionally substituted by a halogen, cyano or C₁₋₆ alkoxy

group or $-NR^5R^6$ represents a nitrogen containing heterocycl group optionally substituted by one or two $=O$ groups.

15. A compound of formula (I) as defined in claim 14 wherein R^5 and R^6 independently represent hydrogen, C_{1-6} alkyl, $-C_{3-8}$ cycloalkyl or $-C_{1-6}$ alkyl- C_{3-8} cycloalkyl.

5 16. A compound of formula (I) as defined in any one of claims 1 to 15 wherein n represents 0 or 1.

10 17. A compound of formula (I) as defined in claim 16 wherein n represents 1 and R^3 represents a halogen atom or a cyano group.

18. A compound of formula (I) as defined in claim 16 wherein n represents 0.

15 19. A compound according to claim 1 which is a compound of formula E1-E288 or a pharmaceutically acceptable salt thereof.

20. A compound of formula (I) as defined in claim 1 which is:

5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy)-pyrazine-2-carboxylic acid

20 methyl amide; or

1-{6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone;

or a pharmaceutically acceptable salt thereof.

25 21. A compound of formula (I) as defined in claim 1 which is 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy)-N-methyl-nicotinamide or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition which comprises the compound of formula 30 (I) as defined in any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

23. A compound as defined in any one of claims 1 to 21 for use in therapy.

35 24. A compound as defined in any one of claims 1 to 21 for use in the treatment of neurological diseases.

25. Use of a compound as defined in any one of claims 1 to 21 in the manufacture of a medicament for the treatment of neurological diseases.


26. A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof.

5 27. A pharmaceutical composition for use in the treatment of neurological diseases which comprises the compound of formula (I) as defined in any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

10 28. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)


15



(II)

wherein R¹, R³ and n are as defined in claim 1, with a compound of formula R²-L¹, wherein R² is as defined in claim 1 for R² or a group convertible thereto and L¹ represents a suitable leaving group such as a halogen atom or an optionally activated hydroxyl group;

20 (b) reacting a compound of formula (III)



(III)

25 wherein R², R³ and n are as defined in claim 1, with a compound of formula R¹-L², wherein R¹ is as defined in claim 1 for R¹ or a group convertible thereto and L² represents a suitable leaving group such as a halogen atom; or

30 (c) reacting a compound of formula (III) as defined in claim 1, with a ketone of formula R¹=O, wherein R¹ is as defined in claim 1 for R¹ or a group convertible thereto; or

(d) deprotecting a compound of formula (I) which is protected; and

(e) interconversion to other compounds of formula (I).